BridgeBio Pharma BBIO Net gains (losses) on investments
Net gains (losses) on investments at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's net gains (losses) on investments?
- BridgeBio Pharma (BBIO) reported net gains (losses) on investments of -$18.28M in Q1 2026.
- How has BridgeBio Pharma's net gains (losses) on investments changed year-over-year?
- BridgeBio Pharma's net gains (losses) on investments decreased by 17.5% year-over-year, from -$15.56M to -$18.28M.
- What is the long-term trend for BridgeBio Pharma's net gains (losses) on investments?
- Over 2 years (2021 to 2025), BridgeBio Pharma's net gains (losses) on investments has grown at a -100.0% compound annual growth rate (CAGR), from $29.91M to $0.
- What does net gains (losses) on investments mean?
- The non-cash change in value of the company's investment holdings.
- How do you interpret net gains (losses) on investments?
- An increase indicates positive valuation adjustments in the investment portfolio, while a decrease signals impairment or market value decline.
- How does net gains (losses) on investments compare across companies?
- Common in biotech firms with strategic minority stakes or venture-like investment arms.